Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Optoderma takes on global psoriasis

This article was originally published in The Rose Sheet

Executive Summary

Company's products for the treatment of psoriasis will be available in the U.S., Canada and Mexico at the end of the month, it announces Nov. 21. Distribution in the U.S. will follow FDA registration as an over-the-counter drug. Optoderma also will expand to 21 countries in the Middle East around the same time through a distribution agreement with a United Arab Emirates company, firm adds. "Highly effective" Optoderma - which comes in cream, lotion and gel form for various applications - is currently sold throughout Europe, as well as online. In Germany, the product's turnover quintupled between January and September of this year, firm adds...



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts